Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Lambert Busque is active.

Publication


Featured researches published by Lambert Busque.


Blood | 2009

Skewing of X-inactivation ratios in blood cells of aging women is confirmed by independent methodologies

Lambert Busque; Yves Paquette; Sylvie Provost; Denis-Claude Roy; Ross L. Levine; Luigina Mollica; D. Gary Gilliland

Nonrandom X-chromosome inactivation (XCI), also known as skewing, has been documented in the blood cells of a significant proportion of normal aging women by the use of methylation-based assays at the polymorphic human androgen receptor locus (HUMARA). Recent data obtained with a new transcription-based XCI determination method, termed suppressive polymerase chain reaction (PCR), has shed controversy over the validity of XCI ratio results obtained with HUMARA. To resolve this disparity, we analyzed XCI in polymorphonuclear leukocytes of a large cohort of women aged 43 to 100 years with the use of HUMARA (n=100), a TaqMan single nucleotide polymorphism (SNP) assay (n=90), and the suppressive polymerase chain reaction (PCR) assay (n=67). The 3 methods yielded similar skewing incidences (42%, 38%, and 40%, respectively), and highly concordant XCI ratios. This confirms that the skewing of XCI ratio seen in blood cells of aging women is a bona fide and robust biologic phenomenon.


Nucleic Acids Research | 1994

An expression based clonality assay at the human androgen receptor locus (HUMARA) on chromosome X

Lambert Busque; Jiguang Zhu; David DeHart; Barbara B. Griffith; Cheryl L. Willman; Rona S. Carroll; Peter McL. Black; D.G. Gilliland


Cancer Research | 1995

Analysis of Meningiomas by Methylation- and Transcription-based Clonality Assays

Jiguang Zhu; Matthew P. Frosch; Lambert Busque; Alan H. Beggs; Kathleen Dashner; D. Gary Gilliland; Peter McL. Black


Journal of Clinical Oncology | 2011

Open-label study evaluating change in chronic low-grade (LG) non-hematologic (heme) adverse events (AEs) in Philadelphia positive (Ph+) CML-CP patients (pts) switched from imatinib (IM) to nilotinib (NL).

Jorge Cortes; Carole B. Miller; J H Lipton; Lambert Busque; Luke P. Akard; Javier Pinilla-Ibarz; Solveig G. Ericson; Michael J. Mauro


Experimental Hematology | 2017

Single UM171 expanded cord blood transplant is feasible and safe, accelerates engraftment, reduces hospitalization length and most importantly improves HLA matching

Sandra Cohen; Jean Roy; Silvy Lachance; Anne Marinier; Jean Sébastien Delisle; Denis Roy; Lambert Busque; Imran Ahmad; Nadia M. Bambace; Lea Bernard; Thomas Kiss; Fannie Larochelle; Pierre Caudrier; Séverine Landais; Sébastien Lemieux; Peter W. Zandstra; Guy Sauvageau


Blood | 2011

Effect of Switching to Nilotinib in Patients with Imatinib-Related Low-Grade Non-Hematologic Adverse Events

Jeffrey H. Lipton; Michael J. Mauro; Sikander Ailawadhi; Carole B. Miller; Lambert Busque; Luke P. Akard; Javier Pinilla-Ibarz; Solveig G. Ericson; Jinay Shah; Jorge Cortes


Blood | 2009

Response: To be skewed or not to be? This is no longer the question

Lambert Busque; Yves Paquette; Luigina Mollica; Denis-Claude Roy; Ross L. Levine; D. Gary Gilliland


Journal of Clinical Oncology | 2017

Analysis of imatinib (IM)-related, low-grade (LG), non-hematologic (heme) adverse events (AEs) in patients (pts) with chronic myeloid leukemia (CML) switched to nilotinib (NIL): ENRICH study update.

Michael J. Mauro; Jeffrey H. Lipton; Carole B. Miller; Sikander Ailawadhi; Lambert Busque; Luke P. Akard; Javier Pinilla-Ibarz; Solveig G. Ericson; Felice P. Lin; Jorge Cortes


/data/revues/00029343/v99i1/S0002934399801120/ | 2011

Natural killer cell lymphoproliferative disease associated with neuropathy

David Leitenberg; Richard N. Eisen; Jonathan Goldstein; Lambert Busque; Henry M. Rinder; Peter K. Stys; Martin E. Katz; D. Gary Gilliland; Brian R. Smith


Archive | 2010

JAK2V617F-negative ET and MMM patients with clonal hematopoiesis JAK2V617F in PV but not ET/MMM, and identifies a subset of assessment reveal a strong association between clonality and X-inactivation-based clonality analysis and quantitative JAK2V617F

Gary Gilliland; Lambert Busque; Ross L. Levine; Claude Belisle; Martha Wadleigh; David Zahrieh

Collaboration


Dive into the Lambert Busque's collaboration.

Top Co-Authors

Avatar

Denis-Claude Roy

Hôpital Maisonneuve-Rosemont

View shared research outputs
Top Co-Authors

Avatar

Ross L. Levine

Memorial Sloan Kettering Cancer Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jorge Cortes

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Michael J. Mauro

Memorial Sloan Kettering Cancer Center

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge